Neuroscience Research Australia and the University of New South Wales, Sydney, 2031, Australia.
Transl Neurodegener. 2012 Jan 13;1(1):2. doi: 10.1186/2047-9158-1-2.
The A53T mutation in the α-synuclein gene causes autosomal-dominant Lewy body Parkinson's disease (PD). Cultured cell models have linked this mutation to increased cell macroautophagy, although evidence of enhanced macroautophagy in patients with this mutation has not been assessed.
To determine whether macroautophagy is increased by the A53T α-synuclein gene mutation in PD patients and cell models.
Formalin-fixed paraffin-embedded 10 μm-thick tissue sections from the substantia nigra and anterior cingulate cortex of two PD patients with the A53T α-synuclein gene mutation were compared with four sporadic PD cases and four controls obtained from the Sydney Brain Bank. Lewy bodies were isolated from frontal cortex of a case with late stage PD (recruited from South Australian Brain Bank). Immunohistochemistry was performed for α-synuclein and the macroautophagy markers autophagy-specific gene (ATG) 5, ATG6/Beclin1 and ATG8/LC3. SH-SY5Y cells were transfected with wild type or A53T mutant α-synuclein plasmids and observable changes in macroautophagy marker protein levels assessed using Western blotting.
α-Synuclein immunoreactive neurites and dots were more numerous in patients with A53T mutations compared with late stage sporadic PD patients, and perinuclear cytoplasmic α-synuclein aggregates were observed in the α-synuclein A53T gene transfected SH-SY5Y cells compared to wild type transfections. All PD patients (with or without A53T mutations) had increased immunohistochemical evidence for macroautophagy compared with controls, and the levels of the ATG5 complex were equally increased in wild type and A53T α-synuclein gene transfected cells compared to controls.
Despite increased α-synuclein accumulation with A53T mutations, macroautophagy is not increased above that observed in sporadic patients with PD or in cells transfected with wild type α-synuclein, suggesting that mutated α-synuclein protein is not removed by macroautophagy.
α-突触核蛋白基因中的 A53T 突变导致常染色体显性遗传路易体帕金森病(PD)。培养的细胞模型将这种突变与细胞巨自噬增加联系起来,尽管尚未评估这种突变患者的巨自噬是否增强。
确定 A53Tα-突触核蛋白基因突变是否在 PD 患者和细胞模型中增加巨自噬。
将两名 A53Tα-突触核蛋白基因突变的 PD 患者的福尔马林固定石蜡包埋 10μm 厚组织切片与四名散发性 PD 病例和四名来自悉尼大脑库的对照进行比较。从晚期 PD 患者(从南澳大利亚大脑库招募)的额叶皮层中分离出路易体。进行α-突触核蛋白和巨自噬标志物自噬特异性基因(ATG)5、ATG6/Beclin1 和 ATG8/LC3 的免疫组织化学染色。用野生型或 A53T 突变α-突触核蛋白质粒转染 SH-SY5Y 细胞,并使用 Western blot 评估巨自噬标志物蛋白水平的可见变化。
与晚期散发性 PD 患者相比,A53T 突变患者的α-突触核蛋白免疫反应性神经突和斑点更多,并且在 A53T 基因转染的 SH-SY5Y 细胞中观察到核周细胞质α-突触核蛋白聚集体,与野生型转染相比。与对照组相比,所有 PD 患者(无论是否存在 A53T 突变)的巨自噬免疫组织化学证据均增加,并且与对照组相比,野生型和 A53Tα-突触核蛋白基因转染细胞中的 ATG5 复合物水平同样增加。
尽管 A53T 突变导致α-突触核蛋白积累增加,但巨自噬并未增加到散发性 PD 患者或转染野生型α-突触核蛋白的细胞中观察到的水平,这表明突变的α-突触核蛋白蛋白不能通过巨自噬清除。